European Investment Bank invests in Cancer treatments

This financing is to accelerate the development of new therapies to treat severe blood cancers and solid tumors, including further clinical development of the flagship project RVU120. RVU120 is a selective CDK8 kinase inhibitor in clinical development for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as solid tumors.